BMJ Case Reports 2017; doi:10.1136/bcr-2017-222063
  • Novel treatment (new drug/intervention; established drug/procedure in new situation)

Durable complete remission with combination chemotherapy and bortezomib in HIV-associated plasmablastic lymphoma

  1. Navid Sadeghi2,3
  1. 1Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA
  2. 2Parkland Health and Hospital System, Dallas, Texas, USA
  3. 3Division of Hematology and Oncology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
  1. Correspondence to Navid Sadeghi, navid.sadeghi{at}
  • Accepted 25 September 2017
  • Published 9 October 2017


Plasmablastic lymphoma (PBL) is an aggressive form of non-Hodgkin’s lymphoma (NHL) classically seen in patients infected with the human immunodeficiency virus, but can also be seen in other immunocompromised states such as transplant recipients, autoimmune diseases and the elderly. PBL is generally associated with a poor prognosis despite chemotherapy. There is evidence supporting the use of bortezomib in combination with standard chemotherapy to achieve durable responses in patients with PBL. We describe a patient with acquired immunodeficiency syndrome who presented with rectal pain and bright red blood per rectum. He was diagnosed with stage IVA PBL with anorectal, nodal, calvarial and hepatic involvement. Along with highly active antiretroviral therapy, he was treated with six cycles of dose adjusted etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (DA-EPOCH) plus bortezomib resulting in durable complete remission 30 months after diagnosis.


  • Contributors NA, AG and NS were involved in the conception and design, acquisition and analysis of data, drafting the article or revising it critically for important intellectual content and gave final approval of the version published.

  • Competing interests None declared.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Register for free content

The full text of all Editor's Choice articles and summaries of every article are free without registration

The full text of Images in ... articles are free to registered users

Only fellows can access the full text of case reports (apart from Editor's Choice) - become a fellow today, or encourage your institution to, so that together we can grow and develop this resource

Don't forget to sign up for content alerts so you keep up to date with all the case reports as they are published, and let us know what you think by commenting on the Editor's blog

Navigate This Article